Free Trial
NASDAQ:CHRS

Coherus Oncology (CHRS) Stock Price, News & Analysis

Coherus Oncology logo
$0.53 0.00 (0.00%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$0.52 0.00 (-0.67%)
As of 11/13/2026 07:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Coherus Oncology Stock (NASDAQ:CHRS)

Advanced

Key Stats

Today's Range
$0.50
▼
$0.54
50-Day Range
$0.53
▼
$1.43
52-Week Range
$0.50
▼
$2.62
Volume
4.31 million shs
Average Volume
2.35 million shs
Market Capitalization
$81.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00
Consensus Rating
Moderate Buy

Company Overview

Coherus Oncology, formerly Coherus BioSciences, is a biopharmaceutical company focused on developing and commercializing cancer treatments. Its portfolio includes LOQTORZI (toripalimab-tpzi), an immune checkpoint inhibitor that targets PD-1 and is approved in the United States for certain patients with nasopharyngeal cancer.

The company is also advancing a pipeline of investigational immuno-oncology medicines. Coherus historically built its business around biosimilar medicines before shifting its focus to oncology.

Coherus is headquartered in the United States and holds U.S. commercial rights to LOQTORZI. The drug was developed by China-based Junshi Biosciences, which partnered with Coherus for its commercialization in the United States.

AI Generated. May Contain Errors.

Coherus Oncology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
34th Percentile Overall Score

CHRS MarketRank™: 
1.69352708058 of 5 stars

Coherus Oncology scored higher than 34% of companies evaluated by MarketBeat, and ranked 737th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Coherus Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Coherus Oncology has a consensus price target of $11.00, representing about 1,993.2% upside from its current price of $0.53.

  • Amount of Analyst Coverage

    Coherus Oncology has only been the subject of 2 research reports in the past 90 days.

  • Read more about Coherus Oncology's stock forecast and price target.
  • Earnings Growth

    Earnings for Coherus Oncology are expected to remain at ($0.83) per share in the coming year.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Coherus Oncology is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Coherus Oncology is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Coherus Oncology has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    8.87% of the float of Coherus Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Coherus Oncology has a short interest ratio ("days to cover") of 8.2.
  • Change versus previous month

    Short interest in Coherus Oncology has recently increased by 2.09%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Coherus Oncology does not currently pay a dividend.

  • Dividend Growth

    Coherus Oncology does not have a long track record of dividend growth.

  • News Sentiment

    Coherus Oncology has a news sentiment score of -0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for Coherus Oncology this week, compared to 3 articles on an average week.
  • Search Interest

    Only 1 people have searched for CHRS on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Coherus Oncology to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Coherus Oncology insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    7.22% of the stock of Coherus Oncology is held by insiders.

  • Percentage Held by Institutions

    72.82% of the stock of Coherus Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Coherus Oncology's insider trading history.
Receive CHRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coherus Oncology and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CHRS Stock News Headlines

Coherus Oncology (NASDAQ:CHRS) Stock Rating Lowered by Wall Street Zen
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
Coherus Oncology (CHRS) Q3 2026 Earnings Call Transcript
See More Headlines

CHRS Stock Analysis - Frequently Asked Questions

Coherus Oncology's stock was trading at $1.42 on January 1st, 2026. Since then, CHRS stock has decreased by 63.0% and is now trading at $0.5255.

Coherus Oncology, Inc. (NASDAQ:CHRS) posted its earnings results on Monday, November, 9th. The biotechnology company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by $0.03. The biotechnology company had revenue of $14.27 million for the quarter, compared to analyst estimates of $15.90 million. Coherus Oncology had a negative trailing twelve-month return on equity of 274.46% and a negative net margin of 253.43%.
Read the conference call transcript
.

Coherus Oncology subsidiaries include InteKrin, Coherus Intermediate Corp, InteKrin Russia, and InteKrin Therapeutics Inc..

Coherus Oncology (CHRS) raised $85 million in an initial public offering (IPO) on Thursday, November 6th 2014. The company issued 6,296,300 shares at a price of $12.00-$15.00 per share.

Top institutional shareholders of Coherus Oncology include State Street Corp (1.57%), Empowered Funds LLC (0.11%), Tyche Wealth Partners LLC (0.09%) and Ieq Capital LLC (0.02%). Insiders that own company stock include Dennis M Lanfear and Mats Wahlstrom.
View institutional ownership trends
.

Shares of CHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Coherus Oncology investors own include NVIDIA (NVDA), Exelixis (EXEL), Viking Therapeutics (VKTX), Iovance Biotherapeutics (IOVA), TG Therapeutics (TGTX), CRISPR Therapeutics (CRSP) and Intel (INTC).

Company Calendar

Last Earnings
11/09/2026
Today
11/15/2026
Jefferies Global Healthcare Conference
11/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CHRS
CIK
1512762
Fax
N/A
Employees
144
Year Founded
2010

Price Target and Rating

High Price Target
$12.00
Low Price Target
$10.00
Potential Upside/Downside
+1,993.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.97)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$168.02 million
Net Margins
-253.43%
Pretax Margin
-289.91%
Return on Equity
-274.46%
Return on Assets
-69.87%

Debt

Debt-to-Equity Ratio
2.08
Current Ratio
1.51
Quick Ratio
1.45

Sales & Book Value

Annual Sales
$42.17 million
Price / Sales
1.93
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.50 per share
Price / Book
1.05

Miscellaneous

Outstanding Shares
154,500,000
Free Float
143,346,000
Market Cap
$81.19 million
Optionable
Optionable
Beta
1.03

Social Links

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (NASDAQ:CHRS) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners